Its operating profits for the 3rd quarter 2010 have recorded 24 billion won, down 21.12% compared with the same period of 2009 (30.4 billion). It shows that the company's profitability is seriously worsening.
And Its net profit for the 3rd quarter 2010 has recorded about 16.1 billion won, down 24.28% compared with the same period of 2009 (about 21.2 billion won).
Bukwang Pharm's declining profitability has been expected by market experts since the safety of 'Levovir' -its proprietary drug for hepatitis B virus- was doubted (myasthenia gravis' side effect).
But Bukwang Pharm, well-informed sources say, has not yet secured new growth engines to resolve a crisis.
According to the UBIST's data, Levovir's(Clevudine) amount of prescription out of hospital has fallen by 26.01% , from 17.3 billion won in 2009 to 12.8 billion won in 2010.
Such decrease is due to the reluctance of doctors to prescribe that drug since its safety issue has been raised.
It is feared that the safety issue of 'Clevudine' may also cause a negative effect on its phase 3 trials and its application for the authorization that are now underway in China. - Healthkoreanews, Korean online medical newspaper -
[기사 더 보기]
-. 부광약품, 레보비르 부작용 여파 수익성 ‘곤두박질’
